Community Practice Connections™: Chronic Kidney Disease and T2D: Evolving Strategies in Diagnosis and Treatment

Released On
November 24, 2021

Expires On
July 28, 2022

Media Type

Completion Time
60 minutes

Cardiology, Endocrinology, Nephrology

Diabetes, Heart Disease, Kidney Disease, Cardiovascular Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward all attendees of the American Diabetes Association’s Virtual 81st Scientific Sessions: primary care physicians, diabetologists, endocrinologists, cardiologists, nephrologists, certified diabetes educators, nurse practitioners, physician assistants, and other health care practitioners who treat patients with CKD.

Activity Overview

Diabetic kidney disease is a disease multiplier that increases the risk of stroke, cardiac, and vascular disease, yet almost 50% of patients with diabetes are not routinely screened to allow for diagnosis and appropriate treatment. Newer classes of glucose-lowering agents have demonstrated both renal and cardiac benefits for patients with diabetes, and the first class of agents for treatment of chronic kidney disease (CKD) has recently been approved.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the virtual symposium at the American Diabetes Association annual meeting held June 27, 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with diabetes and putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • List recommended diagnostic practices for CKD in patients with T2D
  • Elaborate on the relationship between CKD and cardiovascular and renal outcomes
  • Discuss the complex pathophysiology of CKD and emerging approaches to intervene in disease progression
  • Evaluate the efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists and other therapies under investigation for the treatment of patients with CKD




George Bakris, MD

Professor of Medicine
Director, Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL


Jennifer Green, MD

Professor of Medicine
Duke University
Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition
Duke Clinical Research Institute
Durham, NC


Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Disclosures of Conflicts of Interest

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

George Bakris, MD
  • Grant Research Support : Steering committee of trials: Alnylam Pharmaceuticals, Bayer HealthCare, Novo Nordisk, Quantum Genomics, Vascular Dynamics
  • Consultant: Alnylam Pharmaceuticals, AstraZeneca, Bayer HealthCare, Horizon Therapeutics, Ionis Pharmaceuticals, KBP Biosciences, Merck & Co, Novo Nordisk, Quantum Genomics, Vascular Dynamics
Jennifer Green, MD
  • Grant Research Support Boehringer Ingelheim/Eli Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Merck & Co, Sanofi/Lexicon Pharmaceuticals
  • Consultant : AstraZeneca, Boehringer Ingelheim/Eli Lilly and Company, Hawthorne Effect/Omada Health, Novo Nordisk, Pfizer, Sanofi

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.